1. Vitamin D Related/Nuclear Receptor Apoptosis
  2. VD/VDR Apoptosis
  3. Eldecalcitol

Eldecalcitol  (Synonyms: ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3)

Cat. No.: HY-A0020 Purity: 99.86%
COA Handling Instructions

Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1.

For research use only. We do not sell to patients.

Eldecalcitol Chemical Structure

Eldecalcitol Chemical Structure

CAS No. : 104121-92-8

Size Price Stock Quantity
1 mg USD 160 In-stock
5 mg USD 695 In-stock
10 mg USD 1200 In-stock
25 mg USD 2400 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Eldecalcitol:

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Eldecalcitol

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1[1][2][3][4].

In Vitro

Eldecalcitol (0-50 nM; 24 h) displays no cytotoxicity, and (0.5-50 nM; 24 h) reduces cell death induced by LPS (5 μg/mL)[2].
Eldecalcitol (5 nM; 24 h) inhibits the LPS-induced pyroptosis by activating Nrf2 and its effector molecule HO-1[2].
Eldecalcitol (0.5-50 nM; 24 h) exhibits anti-pyroptotic ability, and decreases NLRP3, caspase-1, and IL-1β expression dose-dependently[3].
Eldecalcitol (0.04-40 nM; 0-48 h) inhibits the proliferation and migration of SCC-15 and CAL-27 cells[3].
Eldecalcitol (0.4 nM; 48 h) arrests cell cycle at G0/G1 phase and induces apoptosis by suppressing the expression of GPx-1 (glutathione peroxidase) in OSCC cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[2]

Cell Line: Human gingival fibroblasts (HGFs)
Concentration: 0, 0.5, 5, and 50 nM
Incubation Time: 24 hours
Result: Decreased TLR4, NLRP3, caspase-1 p20, ASC, and GSDMD-N level in a dose-dependent manner compared with the group treated with LPS.
Reduced the release of IL-1β and IL-18 induced by LPS to normal levels.

Cell Proliferation Assay[3]

Cell Line: SCC-15 and CAL-27 cells
Concentration: 0, 0.04, 0.4, 4, and 40 nM
Incubation Time: 6, 8, 12, 24, 48 hours
Result: Inhibited the cell viability of the OSCC cells to reach 50% at 24 h with 0.4 nM.

Cell Proliferation Assay[3]

Cell Line: OSCC cells
Concentration: 0.4 nM
Incubation Time: 48 hours
Result: Increased the proportion of cells at the late phases of apoptosis from 7.1% to 16.1%.
Upregulated Bax and caspase-3, downregulated Bcl-2.
Significantly triggered apoptosis in SCC- 15 and CAL- 27 cells.
In Vivo

Eldecalcitol (0.5 μg/kg; p.o.; twice a week for 4 weeks) displays anti-cancer effect by GPX-1 (glutathione peroxidase) inhibition[3].
Eldecalcitol (10, 30, or 90 ng/kg; p.o.; 5-times per week for 12 weeks), as a more potent vitamin D3 analog, stimulates focal bone formation (minimodeling) and suppresses bone resorption more strongly than does calcitriol[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Xenograft tumor model in mice (male athymic nude BALB/c mice)[3]
Dosage: 0.5 μg/kg
Administration: Oral gavage; twice a week for 4 weeks
Result: Reduced the growth rate of tumors, and downregulated the expression levels of PCNA and MMP- 2 and upregulated the expression of Bax in the tumors.
Resulted in decrease of proliferation, the inhibition of migration, and the promotion of apoptosis.
Animal Model: Ovariectomized (OVX) rat model[4]
Dosage: 10, 30, or 90 ng/kg
Administration: Oral gavage; 5-times per week for 12 weeks
Result: Increased the lumbar and femoral BMD in a dose dependent manner. Stimulated focal bone formation that started without prior bone resorption, a process known as bone minimodeling.
Clinical Trial
Molecular Weight

490.72

Formula

C30H50O5

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O[C@H]1[C@@H](OCCCO)[C@H](O)C(/C(C1)=C\C=C2[C@]3([H])CC[C@H]([C@H](C)CCCC(C)(O)C)[C@@]3(C)CCC\2)=C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility
In Vitro: 

Methanol : 8.33 mg/mL (16.98 mM; Need ultrasonic)

DMSO : 3.33 mg/mL (6.79 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0378 mL 10.1891 mL 20.3782 mL
5 mM 0.4076 mL 2.0378 mL 4.0756 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.94%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / Methanol 1 mM 2.0378 mL 10.1891 mL 20.3782 mL 50.9455 mL
5 mM 0.4076 mL 2.0378 mL 4.0756 mL 10.1891 mL
Methanol 10 mM 0.2038 mL 1.0189 mL 2.0378 mL 5.0946 mL
15 mM 0.1359 mL 0.6793 mL 1.3585 mL 3.3964 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Eldecalcitol Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Eldecalcitol
Cat. No.:
HY-A0020
Quantity:
MCE Japan Authorized Agent: